This page provides a collection of articles, frequently asked questions and interviews with international MPN specialist haematologists and immunologists about COVID-19 and COVID-19 vaccinations.

As of October 2021, from quality evidence based sources, we have noted four important findings relating to COVID-19 and MPN patients.

  1. It is recommended that MPN patients be vaccinated against COVID-19.
  2. Third dose – October 2021 advice from ATAGI recommends a third primary dose of vaccine for severely immunocompromised patients. The advice further elaborates that this includes patients with haematological malignancies. There is advice about particular vaccines and the timing of a third dose, which should be exactly within 2-6 months of your second dose. If you have queries, we suggest that you reach out to your GP or specialist.
  3. Vaccinated MPN patients should continue to follow COVID-19 safe protocols, including following risk mitigation strategies (mask wearing and social distancing) and having family and household contacts vaccinated, although antibody responses from MPN patients to COVID-19 vaccines are reportedly effective.
  4. For MPN patients on ruxolitinib therapy who have a COVID-19 diagnosis, strong advice is that ruxolitinib treatment should continue during treatment for COVID-19.

COVID-19 vaccine specific information for haematology patients

COVID-19 vaccinations – Leukaemia Foundation (Australia) – regularly updated, evidence based information for Australian blood cancer patients.
The page includes a link to the September 2021 webinar ‘COVID-19 vaccinations, fact and fiction’.

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement – May 2021

ATAGI Joint statement from ATAGI and Haematology Society of Australia and New Zealand, May 2021

ATAGI ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised, October 2021

COVID-19 Vaccine in patients with haematological disorders – British Society for Haematology guidelines

NCCN COVID-19 vaccine recommendations for cancer patients – USA’s National Comprehensive Cancer Network recommendations – regularly updated, 2021

COVID-19 and MPN specific information 

What are the long term effects of COVID 19 in patients with MPN – courtesy of MPN-Hub, short video from Dr Tiziano Barbui, July 2021

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib,
2021, Nature Public Health Emergency Collection

Essential Thrombocythemia is associated with a higher risk of thrombosis during COVID 19 – MPN-Hub, March 2021

COVID-19 Astra Zeneca vaccine and the risk of blood clots – MPN Voice UK – April 2021

COVID-19 and Myeloproliferative Neoplasms: Frequently Asked Questions – American Society of Hematology

Ruben Mesa short video on MPNs and COVID-19 – courtesy of the MPN Advocacy & Education International

More general COVID-19 information

New Clinical Guidelines on COVID-19 Published for Haematology and Oncology – Medical Journal of Australia

Cancer and COVID-19 – Cancer Council of Australia

Blood Cancer and COVID-19 – Leukaemia Foundation

COVID-19 information in graphics, including translations – NSW government

Translated COVID-19 information  – Victorian government

CORONACAST podcast – the ABC’s Dr Norman Swan

 

Non COVID-19 related MPN guidelines and articles, including latest information from ASH are available HERE.

Keeping well with an MPN

In these uncertain times it’s even more important to look after our health when we have an MPN.
Our website has several pages dedicated to helping you to keep well with an MPN. They include:

 

Share to: